Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.

摘要: Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment. However, efficacy chemotherapy is limited. Gemcitabine only agent that improves symptoms and confers a modest survival advantage. Many combination therapy regimens have been studied in phase II settings. Eleven randomised III trials conducted to compare gemcitabine-containing gemcitabine monotherapy since became available clinically. The plus capecitabine has demonstrated advantage over gemcitabine, whereas oxaliplatin cisplatin shown improved progression-free or time tumour progression but failed demonstrate gemcitabine. search effective continues. cytotoxic agents molecular targeted hold promise.